Trial intelligence / Profile preview

Phase II open-label multicenter study of MAX-40279 in second-line or later advanced gastric or gastroesophageal junction adenocarcinoma

CTR20220325Phase 2Terminated

Sponsor

Guangzhou Zaiji Medical Technology

Start

Jul 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1